Long COVID Linked to Loss of Dopamine Neurons in the Brain
Long COVID is linked to measurable damage in the brain’s dopamine-releasing neurons, according to a peer-reviewed study published in eBioMedicine. Researchers at the Centre for Addiction and Mental Health utilized positron emission tomography (PET) scans to evaluate dopamine neuron integrity in individuals experiencing long COVID compared with healthy participants, revealing significant biological alterations in the brain regions governing motivation, movement, and thinking.
Essential Findings on Brain Dopamine Systems:
- PET scans revealed significantly lower levels of a dopamine neuron marker across major striatum regions in study participants with long COVID.
- Reductions in the ventral striatum and dorsal putamen correlated directly with symptoms of decreased motivation and slower movement.
- Study authors propose that inflammation damages dopamine neurons, opening potential pathways for treatments using dopamine-boosting medications.
PET Scan Findings Reveal Striatum Alterations
The investigation demonstrated that participants with long COVID exhibit significantly lower levels of a key marker associated with dopamine neuron integrity across major regions of the striatum. The striatum is an area involved in motivation, movement and thinking. Senior author Dr. Jeffrey Meyer noted that the findings supply compelling evidence that long COVID involves the loss of dopamine-releasing neurons.
Specific anatomical reductions mapped directly to distinct clinical symptoms reported by patients. Lower marker concentrations observed within the ventral striatum correlated with a greater loss of drive and motivation. Reductions identified in the dorsal putamen associated with slower physical movement, while alterations in the caudate putamen tied directly to reported memory difficulties.
Inflammation as the Underlying Biological Mechanism
These latest imaging results build directly upon earlier research conducted by the same team at the Centre for Addiction and Mental Health. That prior work detected elevated brain inflammation in regions rich in dopamine neurons. Inflammation can injure dopamine neurons, offering a plausible physiological bridge to explain the persistent neurological sequelae observed in post-COVID conditions.
“We know that inflammation can injure dopamine neurons,” Dr. Jeffrey Meyer stated regarding the combined imaging data. The convergence of elevated brain inflammation markers from prior work and diminished dopamine terminal density in the current study suggests that long COVID functions, at least in part, as a disorder of the brain’s dopamine system.
Because the data indicates a disruption in dopamine availability and signaling, researchers emphasize that existing pharmacological interventions could serve as viable treatment strategies. Medications capable of strengthening dopamine function—such as dopamine precursors and specific inhibitors of dopamine metabolism—represent logical candidates for clinical evaluation.
To test these hypotheses, the research team plans to launch a dedicated clinical trial in collaboration with the University Health Network. This upcoming trial will assess whether targeted therapies designed to restore or enhance dopamine function can successfully alleviate persistent symptoms like fatigue, memory and motivation in individuals suffering from long COVID. The work adds to a growing body of advanced neurological investigations, mirroring related scientific models such as recent projects from Stanford University researchers who engineered mice with functional human neurons to study complex brain disorders.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.